DGAP-Adhoc

SYGNIS AG announces subscription price for new shares in a capital increase to finance the acquisition of Expedeon Holdings Ltd. - Seite 2

sequencing. Based on its proprietary technologies, SYGNIS has developed a
commercial product portfolio addressing key challenges in the fast-growing
fields of molecular biology and next-generation sequencing applications.
Key products include the TruePrime(TM) product line and SensiPhi(R),
licensed to a leading industry partner, for whole genome DNA amplification
and sequencing, as well as the SunScript(TM) Reverse Transcriptase product
family to convert genetic information from RNA molecules back to DNA.
SYGNIS AG is listed on the German Stock Exchange in the Prime Standard
segment (Ticker: LIO1; ISIN: DE000A1RFM03).

### This document is not a securities prospectus and the information
contained herein does not constitute an offer to sell or a solicitation of
an offer to purchase any securities of SYGNIS AG in the Federal Republic of
Germany nor under any other jurisdiction, in particular not where such kind
of offer or solicitation is prohibited or lacks the required permission.
Potential investors in securities of SYGNIS AG are asked to familiarize
themselves with and to observe the respective restrictions.

A decision to invest in the securities of SYGNIS AG should only be made on
the basis of the securities prospectus detailing the public offering of
securities of SYGNIS AG in the Federal Republic of Germany, which, subject
to the approval of the German Federal Financial Supervisory Authority
(BaFin) is anticipated to be published under www.sygnis.com/investors.

The information in this document may not be disseminated outside the
Federal Republic of Germany in particular not in the United States, to U.S.
Persons (as defined in Regulation S of the U.S. Securities Act of 1933) or
to publications with a general circulation in the United States with the
exception of such disclosures or announcements outside the Federal Republic
of Germany which have to be made under the respective mandatory law. Any
person who fails to comply with these restrictions may violate the
securities laws of certain jurisdictions, in particular of the United
States. Securities in SYGNIS AG are not publicly offered outside the
Federal Republic of Germany.

Some statements included in this ad hoc announcement, relating neither to
proven financial results nor other historical data, should be viewed as
forward-looking, i.e. not definite. Such statements are mainly predictions
of future results, trends, plans or goals. These statements should not be
considered to be total guarantees since, given their very nature, they are
subject to known and unknown risks and uncertainties and can be affected by
other factors as a consequence of which the actual results, plans and goals
of SYGNIS AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not undertake
to publicly update or revise these statements in light of new information
or future results or for any other reason. ###


24.06.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: SYGNIS AG
Waldhofer Str. 104
69123 Heidelberg
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.sygnis.com
ISIN: DE000A1RFM03
WKN: A1RFM0
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------